MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 128247 | Name: [Pyr1]-Apelin-13
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

[Pyr1]-Apelin-13 is a highly potent, selective endogenous apelin receptor (APJ) agonist.

Chemical Structure

[Pyr1]-Apelin-13
[Pyr1]-Apelin-13
CAS#217082-60-5

Theoretical Analysis

MedKoo Cat#: 128247

Name: [Pyr1]-Apelin-13

CAS#: 217082-60-5

Chemical Formula: C69H108N22O16S

Exact Mass: 1532.8034

Molecular Weight: 1533.82

Elemental Analysis: C, 54.03; H, 7.10; N, 20.09; O, 16.69; S, 2.09

Price and Availability

Size Price Availability Quantity
1mg USD 450.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
[Pyr1]-Apelin-13; [pGlu1]-Apelin-13); (pGlu1)apelin-13; (Glp1)-Apelin-13; Pyr-apelin-13
IUPAC/Chemical Name
((S)-5-((diaminomethylene)amino)-2-((S)-1-((S)-5-((diaminomethylene)amino)-2-((S)-5-oxopyrrolidine-2-carboxamido)pentanoyl)pyrrolidine-2-carboxamido)pentanoyl)-L-leucyl-L-seryl-L-histidyl-L-lysylglycyl-L-prolyl-L-methionyl-L-prolyl-L-phenylalanine
InChi Key
GGMAXEWLXWJGSF-PEWBXTNBSA-N
InChi Code
InChI=1S/C69H108N22O16S/c1-39(2)32-47(85-57(96)43(17-9-26-76-68(71)72)82-63(102)52-20-12-29-90(52)65(104)45(18-10-27-77-69(73)74)83-58(97)44-22-23-54(93)80-44)59(98)88-50(37-92)61(100)86-48(34-41-35-75-38-79-41)60(99)81-42(16-7-8-25-70)56(95)78-36-55(94)89-28-11-19-51(89)62(101)84-46(24-31-108-3)66(105)91-30-13-21-53(91)64(103)87-49(67(106)107)33-40-14-5-4-6-15-40/h4-6,14-15,35,38-39,42-53,92H,7-13,16-34,36-37,70H2,1-3H3,(H,75,79)(H,78,95)(H,80,93)(H,81,99)(H,82,102)(H,83,97)(H,84,101)(H,85,96)(H,86,100)(H,87,103)(H,88,98)(H,106,107)(H4,71,72,76)(H4,73,74,77)/t42-,43-,44-,45-,46-,47-,48-,49-,50-,51-,52-,53-/m0/s1
SMILES Code
CC(C)C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@@H](CCSC)C(=O)N3CCC[C@H]3C(=O)N[C@@H](CC4=CC=CC=C4)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H]5CCCN5C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H]6CCC(=O)N6
Appearance
To be determined
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 -4 C for short term (days to weeks) or -20 C for long term(months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 1,533.82 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Sahinturk S, Demirel S, Ozyener F, Isbil N. [Pyr1]apelin-13 relaxes the rat thoracic aorta via APJ, NO, AMPK, and potassium channels. Gen Physiol Biophys. 2021 Sep;40(5):427-434. doi: 10.4149/gpb_20210258. PMID: 34602456. 2: Serpooshan V, Sivanesan S, Huang X, Mahmoudi M, Malkovskiy AV, Zhao M, Inayathullah M, Wagh D, Zhang XJ, Metzler S, Bernstein D, Wu JC, Ruiz-Lozano P, Rajadas J. [Pyr1]-Apelin-13 delivery via nano-liposomal encapsulation attenuates pressure overload-induced cardiac dysfunction. Biomaterials. 2015 Jan;37:289-98. doi: 10.1016/j.biomaterials.2014.08.045. Epub 2014 Oct 13. PMID: 25443792; PMCID: PMC5555682. 3: Azizi Y, Imani A, Fanaei H, Khamse S, Parvizi MR, Faghihi M. Post-infarct treatment with [Pyr1]apelin-13 exerts anti-remodelling and anti-apoptotic effects in rats' hearts. Kardiol Pol. 2017;75(6):605-613. doi: 10.5603/KP.a2017.0022. Epub 2017 Feb 9. PMID: 28181211. 4: Vafaei-Nezhad S, Niknazar S, Norouzian M, Abdollahifar MA, Aliaghaei A, Abbaszadeh HA. Therapeutics effects of [Pyr1] apelin-13 on rat contusion model of spinal cord injury: An experimental study. J Chem Neuroanat. 2021 Apr;113:101924. doi: 10.1016/j.jchemneu.2021.101924. Epub 2021 Feb 7. PMID: 33567298. 5: Maguire JJ, Kleinz MJ, Pitkin SL, Davenport AP. [Pyr1]apelin-13 identified as the predominant apelin isoform in the human heart: vasoactive mechanisms and inotropic action in disease. Hypertension. 2009 Sep;54(3):598-604. doi: 10.1161/HYPERTENSIONAHA.109.134619. Epub 2009 Jul 13. PMID: 19597036. 6: Niknazar S, Abbaszadeh HA, Peyvandi H, Rezaei O, Forooghirad H, Khoshsirat S, Peyvandi AA. Protective effect of [Pyr1]-apelin-13 on oxidative stress-induced apoptosis in hair cell-like cells derived from bone marrow mesenchymal stem cells. Eur J Pharmacol. 2019 Jun 15;853:25-32. doi: 10.1016/j.ejphar.2019.03.012. Epub 2019 Mar 12. PMID: 30876980. 7: Azizi Y, Faghihi M, Imani A, Roghani M, Nazari A. Post-infarct treatment with [Pyr1]-apelin-13 reduces myocardial damage through reduction of oxidative injury and nitric oxide enhancement in the rat model of myocardial infarction. Peptides. 2013 Aug;46:76-82. doi: 10.1016/j.peptides.2013.05.006. Epub 2013 May 29. PMID: 23727032.

View History

TA 145

TA 145